Soligenix (SNGX) grants 10,000 stock options to consulting CMO Straube

Rhea-AI Filing Summary

Soligenix consulting chief medical officer Richard Straube reported an equity award in the form of stock options. On December 11, 2025, he received options to acquire 10,000 shares of Soligenix common stock at an exercise price of $1.63 per share, expiring on December 10, 2035.

According to the filing, the option vested immediately as to 25% of the shares, with the remaining 75% vesting in 12 installments (or nearly equal installments) on each three‑month anniversary of December 11, 2025. The filing shows 10,000 derivative securities beneficially owned directly following this transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Straube Richard

(Last) (First) (Middle)

C/O SOLIGENIX, INC.

29 EMMONS DRIVE, SUITE B-10

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SOLIGENIX, INC. [ SNGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CMO (Consulting)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to Buy)(1)	$1.63	12/11/2025		A		10,000		12/11/2025	12/10/2035	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. The stock option vested immediately as to 25% of the shares and vests as to the remaining 75% of the shares in 12 equal installments (or nearly equal installments if the number of remaining shares is not evenly divisible by 12) on each three (3) month anniversary of December 11, 2025.

	/s/ Richard Straube	12/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Soligenix (SNGX) report in this filing?

The filing reports that Richard Straube, Soligenix’s consulting chief medical officer, received a grant of stock options relating to 10,000 shares of common stock.

How many Soligenix (SNGX) stock options were granted to the consulting CMO?

The consulting CMO, Richard Straube, was granted 10,000 stock options, each linked to one share of Soligenix common stock.

What is the exercise price and expiration date of the Soligenix (SNGX) stock options?

The options have an exercise price of $1.63 per share and carry an expiration date of December 10, 2035, as disclosed in the derivative securities table.

How do the Soligenix (SNGX) CMO stock options vest over time?

The stock option vested immediately as to 25% of the shares, with the remaining 75% vesting in 12 equal (or nearly equal) installments on each three‑month anniversary of December 11, 2025.

Does the reporting person hold the Soligenix (SNGX) options directly or indirectly?

The filing states that 10,000 derivative securities are beneficially owned on a direct (D) basis following the reported transaction.

Is the reporting person a director or officer of Soligenix (SNGX)?

The reporting person is identified as an officer of Soligenix with the title “CMO (Consulting)”, not as a director or 10% owner.